Clinical Trials Browser

Prostatic Neoplasms, Castration-Resistant

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

390 enrolled

Gynecologic

Ovarian Neoplasms

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Phase 2 Active not recruiting

10 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05601440 2026-03-27

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

484 enrolled

Breast

Breast Neoplasms

NCT03601923 2026-03-25

Niraparib in Patients With Pancreatic Cancer

Phase 2 Completed

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04288687 2026-03-04

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Completed

11 enrolled 13 charts

Genitourinary

Prostate Adenocarcinoma

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

200 enrolled

Genitourinary

Prostatic Neoplasms

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

63 enrolled

Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT05442749 2026-02-17

PARPi-PANC

Phase 2 Terminated

2 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

66 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05718323 2026-02-06

RAISE

Phase 2 Recruiting

44 enrolled

Thoracic

SCLC,Extensive Stage

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Recruiting

120 enrolled

CNS

Brain Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

Phase 2 Active not recruiting

20 enrolled

CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

Clinical Trials

QUEST

NIRVANA-1

HARMONY

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Niraparib in Patients With Pancreatic Cancer

I-SPY

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

PARPi-PANC

STAR

RAISE

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Niraparib in Tumors Metastatic to the CNS